Jessica A Myers
Overview
Explore the profile of Jessica A Myers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Myers J, Louis T
Health Serv Outcomes Res Methodol
. 2014 Nov;
12(1):29-43.
PMID: 25419169
In observational studies of treatments or interventions, propensity score (PS) adjustment is often useful for controlling bias in estimation of treatment effects. Regression on PS is used most often and...
2.
Kesselheim A, Robertson C, Myers J, Rose S, Gillet V, Ross K, et al.
N Engl J Med
. 2012 Sep;
367(12):1119-27.
PMID: 22992075
Background: The effects of clinical-trial funding on the interpretation of trial results are poorly understood. We examined how such support affects physicians' reactions to trials with a high, medium, or...
3.
Kim S, Schneeweiss S, Myers J, Liu J, Solomon D
Arthritis Rheum
. 2012 Jul;
64(10):3076-82.
PMID: 22782529
Objective: Previous study findings have suggested that patients with chronic diseases such as rheumatoid arthritis (RA) do not receive optimal preventive medical services, including cancer screening tests. This study was...
4.
Reich N, Myers J, Obeng D, Milstone A, Perl T
PLoS One
. 2012 May;
7(4):e35564.
PMID: 22558168
In recent years, the number of studies using a cluster-randomized design has grown dramatically. In addition, the cluster-randomized crossover design has been touted as a methodological advance that can increase...
5.
Kesselheim A, Myers J, Solomon D, Winkelmayer W, Levin R, Avorn J
PLoS One
. 2012 Feb;
7(2):e31894.
PMID: 22363762
Introduction: The Orphan Drug Act encourages drug development for rare conditions. However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of...
6.
Myers J, Rassen J, Gagne J, Huybrechts K, Schneeweiss S, Rothman K, et al.
Am J Epidemiol
. 2011 Oct;
174(11):1213-22.
PMID: 22025356
Recent theoretical studies have shown that conditioning on an instrumental variable (IV), a variable that is associated with exposure but not associated with outcome except through exposure, can increase both...
7.
Kesselheim A, Myers J, Avorn J
JAMA
. 2011 Jun;
305(22):2320-6.
PMID: 21642684
Context: The Orphan Drug Act incentivizes medication development for rare diseases, offering substantial financial benefits to the manufacturer. Orphan products constitute most new drug approvals in oncology, but safety and...
8.
Cosgrove L, Shi L, Creasey D, Anaya-McKivergan M, Myers J, Huybrechts K
PLoS One
. 2011 Apr;
6(4):e18210.
PMID: 21494667
Background: Antidepressant (AD) use has been purported to increase the risk of breast and ovarian cancer, although both epidemiological and pre-clinical studies have reported mixed results. Previous studies in a...
9.
Opryszko M, Majeed S, Hansen P, Myers J, Baba D, Thompson R, et al.
J Water Health
. 2010 Aug;
8(4):687-702.
PMID: 20705980
A randomized controlled trial of four interventions was conducted using tubewells (n=2,486), liquid sodium hypochlorite ('Clorin') distributed with an improved water vessel (n=2,305), hygiene promotion (n=1,877), and a combination of...